Product hub: Capsugel® ZephyrTM – dry-powder inhalation capsule portfolio
Given patient convenience and compatibility with a range of formulations and doses, capsule based dry-powder inhalation (DPI) technology is becoming the preferred DPI drug delivery platform for respiratory and systemic applications.
Lonza’s Capsugel® customised capsules, in both gelatin and hypromellose, are optimised to provide superior performance and compatibility between the capsule/device and capsule/formulation.
Related content from this organisation
- COVID-19 Vaccine Moderna update
- EPR Podcast Episode 2 – Bioavailability enhancement with Dr Deanna Mudie, Lonza
- Moderna invests to increase global supply of its COVID-19 vaccine
- Biologics CDMO market to double in value by 2026, suggests report
- Moving towards the digitalisation of your lab, with the 8th edition of the Paperless Lab Academy® – this year, online